Sjogren's Syndrome Treatment Market Report and Forecast 2025-2034

The Sjogren’s syndrome treatment market was valued at USD 271.02 Million in 2024, driven by increasing incidence of autoimmune diseases across the globe. The market is expected to grow at a CAGR of 3.79% during the forecast period of 2025-2034, with the values likely to reach USD 393.15 Million by 2034.

Sjogren’s Syndrome Treatment Market Overview

Sjogren’s syndrome is a chronic autoimmune disease characterized by the immune system attacking the glands responsible for production of tears and saliva. This condition results in dry eye and dry mouth (also known as sicca symptoms). Nevertheless, it can also affect other body parts like lungs, kidneys, joints, and nerves etc. leading to wide range of symptoms and complications. The treatment for the syndrome includes symptomatic treatment, biologic agents, immune system suppression, and lifestyle adjustments. Nearly 4 % of the world’s population is affected by one of more than 80 different autoimmune diseases.

Sjogren’s Syndrome Treatment Market Growth Drivers

Increasing Research and Development Activities

To curb the burden of the autoimmune disease, the market is witnessing increased research and development of new drugs. There is an increasing involvement of organizations in conducting clinical trials to produce a treatment for the syndrome to help the patients with Sjogren’s syndrome. In November 2023, Amgen presented data from phase 2 trial of dazodalibep, a CD40 ligand antagonist in Sjögren's syndrome at American College of Rheumatology. The clinical trial was a randomized, double-blind, placebo-controlled crossover study evaluating two Sjögren's populations. The findings from the study demonstrated positive results that dazodalibep may improve both the systemic and symptomatic disease burden of people living with Sjögren's syndrome.

Growth in Strategic Partnerships and Mergers to Meet Rising Sjogren’s Syndrome Treatment Market Demand

In February 2024, PrecisionLife and Metrodora Institute collaborated to diagnose and treat complex chronic diseases including long COVID, ME/CFS, ALS, Sjögren's syndrome, and many more. Under the agreement, both partners aim to first develop and validate genotypic diagnostics to provide clinicians with an accurate view of patients’ risk of disease. This involves using molecular profiling to understand the underlying disease mechanisms. The insights are projected to help clinicians in making more informed prescribing decisions and identify new areas for drug discovery leading to improve patient outcomes.

Sjogren’s Syndrome Treatment Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

Shift Towards Personalized Medicines

Increasing preference for precision or personalized medicine for Sjogren’s syndrome can be observed in the market. Research on identifying genetics that might predict how a patient responds to specific medications. Biomarkers can be identified for better targeting and with tailored therapies, side effects can be minimized by selecting therapies that align more closely to an individual’s genetic makeup.

Upgraded Diagnostic Tools

Early diagnosis with accuracy is a challenge in Sjogren’s syndrome as the symptoms overlap with other autoimmune diseases, therefore, advanced diagnostic tools are required. Conventional imaging system might not always detect subtle glandular changes; therefore, new imaging technique as salivary gland ultrasonography is being explored to detect structural changes

Increased Research Funding and Collaboration

Biotechnology and pharmaceutical companies are increasing investments to develop more effective treatment options for the syndrome, including non-pharmacological interventions and drug development. There is an increase in funding for well-designed clinical trials necessary for new drug development and to carter to the need of treatment options.

Focus on Symptomatic Relief

The syndrome is marked by dryness of eyes and mouth along with joint fatigue that effects the quality of life. Symptomatic relief improves the daily life of a patient by improving comfort and functionality. The market consists of products that provide symptomatic relief, and the products are also being improved in terms of safety and efficacy.

Sjogren’s Syndrome Treatment Market Segmentation

The EMR’s report titled “Sjogren’s Syndrome Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class

• Antimalarial Quinolines
• Cholinergic Agents
• Corticosteroids
• Others

Market Breakup by Therapy Type

• Targeted Drugs
• Pain Relievers
• Symptom Modulators
• Vaccines
• Surgery
• Others

Market Breakup by Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Sjogren’s Syndrome Treatment Market Share

Market Segmentation Based on Drug Class is Projected to Experience Substantial Growth

Based on drug class, the market segmentation includes antimalarial quinolines, cholinergic agents, corticosteroids among others. Antimalarial quinolones are majorly used for their anti-inflammatory properties that caters to the systemic symptoms of the syndrome. This segment is predicted to observe steady growth because of its efficacy in reducing skin rash and fatigue associated with the syndrome. To address the chief symptoms of Sjogren’s syndrome such as dry eyes and mouth, cholinergic agents are used as they stimulate the secretion of saliva. The demand for cholinergic agents is estimated to grow as the number of diagnosed cases are increasing, thereby increasing the requirement of symptomatic relief.

Corticosteroids are incorporated into the treatment regimen to control severe symptoms involving vital organs like kidneys and lungs. These medications are crucial in managing inflammation. Their use is limited to a short span of time as it can cause long term side effects.

Targeted Drug Therapy Expected to Lead the Market Share

Based on therapy type, the market constitutes targeted drugs, pain relievers, symptom modulators, vaccines, surgery, and others. Targeted drugs such as B cell-depleting agents and inhibitors of B cell activation offer precision treatment by aiming on molecular targets associated with the syndrome. To curb the pain and ease the symptoms, the pain relivers and symptom modulators are expected to witness significant growth. This is also attributed to the widespread use of symptom modulators are the primary concern for Sjogren’s syndrome is to get relief from the symptoms of dry mouth and dry eye. Surgical interventions, though less common, are crucial for severe cases where glandular functionality is heavily compromised.

Sjogren’s Syndrome Treatment Market Analysis by Region

Regionally, the market report offers an insight into United States, EU-4 (including Spain, France, Italy and Germany) along with the United Kingdom, Japan and India. Leading the market with advanced healthcare infrastructure and investments in research and development, United States is projected to hold a significant market share in the forecast period. Increasing incidence of clinical trials in the region is also driving market growth in the region. Surge in investments in healthcare research and government support for innovations is boosting Europe’s Sjogren’s syndrome treatment market. The region also has a well-established infrastructure along with high awareness of autoimmune diseases.

Leading Players in the Sjogren’s Syndrome Treatment Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Denali Therapeutics
• Clovis Oncology
• Horizon Therapeutics Plc
• Sangamo Therapeutics
• AbbVie Inc
• Advanz Pharma
• Biogen Inc
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Hikma Pharmaceuticals PlC
• Johnson and Johnson

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in the Sjogren’s Syndrome Treatment Market Report

• What was the Sjogren’s syndrome treatment market value in 2023?
• What is the Sjogren’s syndrome treatment market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is market segmentation based on drug class?
• What is the market breakup based on therapy type?
• Who are the major distribution channels in the market?
• What are the various route of administration in Sjogren’s syndrome treatment market?
• What are the major factors aiding the Sjogren’s syndrome treatment market demand?
• How has the Sjogren’s syndrome treatment market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How does the prevalence and incidence of autoimmune diseases affect the market landscape?
• What are the major Sjogren’s Syndrome Treatment market trends?
• What drug class will dominate the market share?
• Who are the key players involved in the Sjogren’s syndrome treatment market?
• What is patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.